26 jul: Valuta: Draghi flytter euroen mod ugerekord
26 jul: Spanien/FIH: Draghi beroliger markederne med stærk udmelding
26-07-2012 14:43:00

Woes Of European Pharma Companies On Display During Results Period

Relateret indhold

By Sten Stovall

LONDON--The problems facing Europe's big drug makers were underscored Thursday by Britain's AstraZeneca PLC (AZN) and France's Sanofi SA (SNY), which said the loss of patents on some of their blockbuster drugs and draconian austerity measures imposed by governments in the region will cause their full-year earnings to fall.

Their message echoed that from GlaxoSmithKline PLC (GSK), which Wednesday warned that pricing pressure in Europe and the U.S. will keep its sales flat this year, despite strong growth in Japan and emerging markets. Last week, Swiss drug giant Novartis AG (NVS) said second-quarter sales fell 4%, hurt in part by generic competition to the company's hypertension pill Diovan.

A brighter performance came from Switzerland's Roche Holding AG (ROG.VX), which Thursday reported a drop in first-half profit, mainly due to the closure of a U.S. site, but a 3.5% rise in group sales due to a strong performance from its cancer drugs in the U.S. and emerging markets, and said it was on course to meet its objectives.

But the general picture is one of retrenchment as mounting patent losses squeeze revenue at a number of European drug makers. AstraZeneca and Sanofi are among the most affected due to the U.S. expiries of schizophrenia treatment Seroquel and blood thinner Plavix, respectively. Both companies have responded by cutting jobs and acquiring smaller biotechnology companies with promising new drugs to improve their pipelines of high-priced patented medicines.

Other drug makers are also seeking acquisitions help replenish their pipelines, but the degree of urgency to do deals varies from company to company.

Meanwhile, their profitability is being by the deepening crisis in the euro zone. And while drug companies have faced falling prices in Europe for several years, the situation has gotten much worse recently due to deep budget cuts--particularly in southern Europe--triggered by the euro crisis.

"We're not growing as fast as we hoped at the beginning of the year," Glaxo Chief Executive Andrew Witty said Wednesday, attributing the change to weakness in Europe.

AstraZeneca also warned Thursday about the deepening crisis in Europe.

"Government interventions in the market place continue to take their toll--we estimate the impact for AstraZeneca at around $300 million in the second quarter alone as spending on medicines come under pressure in most parts of the world and especially in Europe," said Simon Lowth, the company's interim chief executive.

Eventual salvation from new drugs is the hope shared by all drug makers. Some are having more luck than others in their search. But analysts believe that the fires of drug discovery are finally being stoked by a growing understanding of how genomics shape the biology of disease. This is leading to promising new treatments that target critical areas of unmet medical need while also increasing the efficacy of interventions geared to the individual patient.

"Our growth in the future will really be dependent on that pipeline being delivered," Glaxo CEO Witty acknowledged Wednesday.

The challenge for all players is that many new treatments may not complete the move from concept to patient in time to plug the yawning revenue gap from a second record year of patent expiries. Analysts say this year's dropoff the patent cliff is the longest and steepest, with a $50 billion loss coming on top of the $30 billion ceded to generics in 2011.

-Write to Sten Stovall at Sten.Stovall@DowJones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 26, 2012 08:43 ET (12:43 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Mærsk: Oil-salg får analytikerne til at rykke på kursmålene

22-08-2017 11:39:54
Analytikerne har primært reageret positivt på A.P. Møller-Mærsks salg af Maersk Oil.Olie- og gasdivisionen sælges til franske Total for 7,45 mia. dollar, eller 47 mia. kr., og det var mere, end de fleste analytikere havde forudset. Den ekstra værdi lægges derfor i mange tilfælde oven i aktiekursen.Eksempelvis har Nykredit lagt 400 kr. til kursmålet alene fra Oil-salget, der var 8 mia. kr. over ana..

Aktier/tendens: Jyske Bank, Matas og Unibrew tager overskrifterne

22-08-2017 08:29:20
Efter en mandag med Mærsk-aktierne i centrum for handelsaktiviteten på den danske børs skifter fokus tirsdag til tre regnskabsaktuelle aktier: Jyske Bank, Matas og Royal Unibrew.Generelt vil der være tale om en relativt afdæmpet start på handelsdagen, vurderer afdelingschef Ole Kjær Jensen fra Sydbank. Impulserne fra Asien er dog let positive, og futures ligger lidt over nulpunktet i Europa.- Der ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Zealand Pharma spås kursdyk: Shortinteresse steget 108 pct. på 30 dage
2
Mærsk: Oil-salg får analytikerne til at rykke på kursmålene
3
Bavarian får godkendt aftale med Janssen af amerikanske myndigheder
4
KORR: Medicinalgigant får prygl på børsen efter finansdirektørs farvel
5
Aktier/tendens: Jyske Bank, Matas og Unibrew tager overskrifterne

Relaterede aktiekurser

Glaxosmithkline PLC ORD .. 1.498,75 1,3% Stigning i aktiekurs
Novartis N 80,65 0,9% Stigning i aktiekurs
Astrazeneca PLC ORD SHS .. 4.429,50 0,3% Stigning i aktiekurs
Sanofi 82,42 0,6% Stigning i aktiekurs
Roche GS 243,80 1,4% Stigning i aktiekurs
GlaxoSmithKline PLC 38,92 0,6% Stigning i aktiekurs
Bristol-Myers Squibb Com.. 57,04 0,7% Stigning i aktiekurs
Astrazeneca PLC 28,85 -0,4% Fald i aktiekurs
Novartis AG 83,35 0,4% Stigning i aktiekurs
Roche I 247,60 1,4% Stigning i aktiekurs
Sanofi American Deposita.. 48,39 0,4% Stigning i aktiekurs
AstraZeneca PLC 467,50 0,2% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. august 2017 16:49:22
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170821.2 - EUROWEB5 - 2017-08-22 16:49:22 - 2017-08-22 16:49:22 - 1 - Website: OKAY